PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00755196
- Locations
- π²π½
IMIC, Mexico City, Distrito Federal, Mexico
Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia
- Conditions
- Fibromyalgia
- Interventions
- Drug: [S,S]-Reboxetine
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 390
- Registration Number
- NCT00754221
- Locations
- π¨π¦
Pfizer Investigational Site, Quebec, Canada
Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
- Conditions
- Osteoporosis
- Interventions
- Drug: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)Drug: bisphosphonates, calcium, and vitamin D
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT00752557
- Locations
- πΊπΈ
Florida Arthritis & Osteoporosis Center, Port Richey, Florida, United States
πΊπΈVictoria Park Imaging, DeLand, Florida, United States
πΊπΈSuncoast Clinical Research Inc, New Port Richey, Florida, United States
A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 89
- Registration Number
- NCT00752505
- Locations
- πΊπΈ
Pfizer Investigational Site, Dallas, Texas, United States
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
- Conditions
- Complicated Intra-abdominal Infections
- Interventions
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 204
- Registration Number
- NCT00752219
- Locations
- πΊπΈ
Cedars-Sinai Medical Center Dept of Surgery, Los Angeles, California, United States
πΊπΈHenry Ford Health System, Detroit, Michigan, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Biological: ACC-001Other: PBSOther: QS-21
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00752232
- Locations
- π―π΅
Kitasato University East Hospital, Kanagawa, Japan
π―π΅Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan
π―π΅Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00751478
- Locations
- π¨π¦
DecisionLine Clinical Research, Toronto, Ontario, Canada
A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension
- Conditions
- GlaucomaOpen Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 268
- Registration Number
- NCT00751127
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT00749944
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00748592